Embolism, Pulmonary Clinical Trial
Official title:
Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in the Treatment of Acute Pulmonary Thromboembolism (PE)
The primary objective is to evaluate the efficacy (as measured by the rate of recurrent symptomatic Venous Thromboembolism [VTE] (i.e., Pulmonary thromboembolism [PE] and Deep Vein Thrombosis [DVT])) and safety of GSK576428 as the initial treatment in subjects with acute PE in an open-label design.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01258140 -
Detection of Pulmonary Embolism With Low-dose CT Pulmonary Angiography
|
N/A | |
| Completed |
NCT05770232 -
Retrospectively Analyze the Risk Factors of VTE in 5774 Patients With Thoracic Trauma From 33 Hospitals in China, and Established a Risk Prediction Model
|
||
| Withdrawn |
NCT03366519 -
Clinical Echography in Emergency Prognostic Evaluation of Pulmonary Embolism: ECU -EP Study.
|
||
| Recruiting |
NCT04731558 -
Pre- vs Postoperative Thromboprophylaxis for Liver Resection
|
Phase 4 | |
| Terminated |
NCT05172115 -
Catheter-Directed Thrombolysis Versus Anticoagulation Monotherapy in Intermediate-High Risk PE
|
Phase 3 |